Search research articles
Contact Us
Filters
Showing results (101-110 of 120) with videos related to
Page
of 12
Sort By:
Journal of Gastroenterology
|
July 19, 2018
Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection
Goki Suda, Masayuki Kurosaki, Jun Itakura, et al.
Biomarker Research
|
September 24, 2025
Long non-coding RNA PWRN4 associated with post-SVR hepatocellular carcinoma: a genome-wide association study
Goki Suda, Masaya Sugiyama, Hayato Hikita, et al.
Journal of Gastroenterology
|
June 1, 2017
Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan
Goki Suda, Norihiro Furusyo, Hidenori Toyoda, et al.
JHEP Reports : Innovation in Hepatology
|
April 17, 2025
Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC
Risako Kohya, Goki Suda, Masatsugu Ohara, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
August 12, 2022
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib
Margherita Rimini, Wonseok Kang, Valentina Burgio, et al.
Hepatology International
|
August 28, 2025
Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Masatsugu Ohara, Goki Suda, Risako Kohya, et al.
Liver Cancer
|
May 16, 2024
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib
Massimo Iavarone, Eleonora Alimenti, Toshifumi Tada, et al.
Journal of Cancer Research and Clinical Oncology
|
March 28, 2023
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients
Margherita Rimini, Mara Persano, Toshifumi Tada, et al.
Targeted Oncology
|
March 15, 2023
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
Margherita Rimini, Mara Persano, Toshifumi Tada, et al.
International Journal of Cancer
|
November 23, 2023
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
Federico Rossari, Toshifumi Tada, Goki Suda, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 120) with videos related to
Sort By:
Page
of 12
Journal of Gastroenterology
|
July 19, 2018
Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection
Goki Suda, Masayuki Kurosaki, Jun Itakura, et al.
Biomarker Research
|
September 24, 2025
Long non-coding RNA PWRN4 associated with post-SVR hepatocellular carcinoma: a genome-wide association study
Goki Suda, Masaya Sugiyama, Hayato Hikita, et al.
Journal of Gastroenterology
|
June 1, 2017
Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan
Goki Suda, Norihiro Furusyo, Hidenori Toyoda, et al.
JHEP Reports : Innovation in Hepatology
|
April 17, 2025
Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC
Risako Kohya, Goki Suda, Masatsugu Ohara, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
August 12, 2022
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib
Margherita Rimini, Wonseok Kang, Valentina Burgio, et al.
Hepatology International
|
August 28, 2025
Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Masatsugu Ohara, Goki Suda, Risako Kohya, et al.
Liver Cancer
|
May 16, 2024
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib
Massimo Iavarone, Eleonora Alimenti, Toshifumi Tada, et al.
Journal of Cancer Research and Clinical Oncology
|
March 28, 2023
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients
Margherita Rimini, Mara Persano, Toshifumi Tada, et al.
Targeted Oncology
|
March 15, 2023
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
Margherita Rimini, Mara Persano, Toshifumi Tada, et al.
International Journal of Cancer
|
November 23, 2023
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma
Federico Rossari, Toshifumi Tada, Goki Suda, et al.
Page
of 12